Suppr超能文献

转移:最新发现与新型治疗策略

Metastasis: recent discoveries and novel treatment strategies.

作者信息

Eccles Suzanne A, Welch Danny R

机构信息

Tumour Biology and Metastasis, Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, UK.

出版信息

Lancet. 2007 May 19;369(9574):1742-57. doi: 10.1016/S0140-6736(07)60781-8.

Abstract

Most cancer deaths are due to the development of metastases, hence the most important improvements in morbidity and mortality will result from prevention (or elimination) of such disseminated disease. Some would argue that treatments directed against metastasis are too late because cells have already escaped from the primary tumour. Such an assertion runs contrary to the significant but (for many common adult cancers) fairly modest improvements in survival following the use of adjuvant radiation and chemotherapy designed to eliminate disseminated cells after surgical removal of the primary tumour. Nonetheless, the debate raises important issues concerning the accurate early identification of clonogenic, metastatic cells, the discovery of novel, tractable targets for therapy, and the monitoring of minimal residual disease. We focus on recent findings regarding intrinsic and extrinsic molecular mechanisms controlling metastasis that determine how, when, and where cancers metastasise, and their implications for patient management in the 21st century.

摘要

大多数癌症死亡是由转移灶的形成所致,因此,发病率和死亡率的最重要改善将源于对这种播散性疾病的预防(或消除)。有些人可能会争辩说,针对转移的治疗为时已晚,因为癌细胞已经从原发肿瘤中逃逸。这种说法与使用辅助放疗和化疗后生存率的显著提高(但对于许多常见的成人癌症而言,提高幅度相当有限)相悖,辅助放疗和化疗旨在在手术切除原发肿瘤后消除播散的细胞。尽管如此,这场争论提出了一些重要问题,涉及克隆性转移细胞的准确早期识别、新型可治疗靶点的发现以及微小残留病的监测。我们关注有关控制转移的内在和外在分子机制的最新发现,这些机制决定了癌症转移的方式、时间和位置及其对21世纪患者管理的影响

相似文献

1
Metastasis: recent discoveries and novel treatment strategies.
Lancet. 2007 May 19;369(9574):1742-57. doi: 10.1016/S0140-6736(07)60781-8.
2
The emerging role of miR-200 family in metastasis: focus on EMT, CSCs, angiogenesis, and anoikis.
Mol Biol Rep. 2021 Oct;48(10):6935-6947. doi: 10.1007/s11033-021-06666-6. Epub 2021 Sep 12.
4
Critical determinants of cancer metastasis: rationale for therapy.
Cancer Chemother Pharmacol. 1999;43 Suppl:S3-10. doi: 10.1007/s002800051091.
6
The challenge of targeting metastasis.
Cancer Metastasis Rev. 2015 Dec;34(4):635-41. doi: 10.1007/s10555-015-9586-9.
7
Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.
Biochim Biophys Acta. 2008 Dec;1786(2):87-104. doi: 10.1016/j.bbcan.2008.07.002. Epub 2008 Jul 22.
8
Lung cancer. 9: Molecular biology of lung cancer: clinical implications.
Thorax. 2003 Oct;58(10):892-900. doi: 10.1136/thorax.58.10.892.
9
Targeting anoikis resistance in prostate cancer metastasis.
Mol Aspects Med. 2010 Apr;31(2):205-14. doi: 10.1016/j.mam.2010.02.001. Epub 2010 Feb 11.
10
Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey.
Cancer Microenviron. 2014 Dec;7(3):117-31. doi: 10.1007/s12307-014-0148-4. Epub 2014 Jun 18.

引用本文的文献

1
The oncolytic avian reovirus p17 protein suppresses invadopodia formation via disruption of TKs5 complexes and oncogenic signaling pathways.
Front Cell Infect Microbiol. 2025 Jun 12;15:1603124. doi: 10.3389/fcimb.2025.1603124. eCollection 2025.
2
The neuroscience of cancer: Focus on neuropeptidergic systems.
Acta Pharm Sin B. 2025 May;15(5):2323-2350. doi: 10.1016/j.apsb.2025.03.025. Epub 2025 Mar 13.
3
Novel metastasis suppressor PI3KC2β is mediated by mTORC1 signalling in breast cancer.
Mol Cancer Res. 2025 May 13. doi: 10.1158/1541-7786.MCR-24-1045.
4
Tumor microbiome: roles in tumor initiation, progression, and therapy.
Mol Biomed. 2025 Feb 8;6(1):9. doi: 10.1186/s43556-025-00248-9.
5
Pan-cancer drivers of metastasis.
Mol Cancer. 2025 Jan 2;24(1):2. doi: 10.1186/s12943-024-02182-w.
7
Unraveling the metastasis-preventing effect of miR-200c in vitro and in vivo.
Mol Oncol. 2025 Apr;19(4):1029-1053. doi: 10.1002/1878-0261.13712. Epub 2024 Oct 15.
8
A relay-type innate immunity activation strategy involving water-soluble NIR-II AIEgen for boosted tumor photo-immunotherapy.
Theranostics. 2024 Aug 5;14(12):4667-4682. doi: 10.7150/thno.95724. eCollection 2024.
10
MicroRNA as Key Players in Hepatocellular Carcinoma: Insights into Their Role in Metastasis.
Biochem Genet. 2025 Apr;63(2):1014-1062. doi: 10.1007/s10528-024-10897-0. Epub 2024 Aug 5.

本文引用的文献

1
Characterizing the tumor response to treatment with combretastatin A4 phosphate.
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):211-7. doi: 10.1016/j.ijrobp.2006.12.051.
3
Target-based approach to inhibitors of histone arginine methyltransferases.
J Med Chem. 2007 May 17;50(10):2319-25. doi: 10.1021/jm061250e. Epub 2007 Apr 14.
4
Development of histone deacetylase inhibitors for cancer treatment.
Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. doi: 10.1586/14737140.7.4.583.
5
Bevacizumab in the management of solid tumors.
Expert Rev Anticancer Ther. 2007 Apr;7(4):433-45. doi: 10.1586/14737140.7.4.433.
6
MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent.
Int J Biochem Cell Biol. 2007;39(7-8):1388-405. doi: 10.1016/j.biocel.2007.02.009. Epub 2007 Feb 16.
7
SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion.
Nat Genet. 2007 Apr;39(4):467-75. doi: 10.1038/ng1997. Epub 2007 Mar 18.
8
Vascular endothelial growth factor (VEGF) inhibition--a critical review.
Anticancer Agents Med Chem. 2007 Mar;7(2):223-45. doi: 10.2174/187152007780058687.
9
10
Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
J Clin Pharm Ther. 2007 Feb;32(1):1-14. doi: 10.1111/j.1365-2710.2007.00800.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验